Gemfibrozil attenuates the inflammatory response and protects rats from abdominal sepsis

Cámara‑Lemarroy,Carlos  R.; Guzman‑De La Garza,Francisco J.; Cordero‑Perez,Paula; Ibarra‑Hernandez,Juan  M.; Muñoz‑Espinosa,Linda  E.; Fernandez‑Garza,Nancy  E.

doi:10.3892/etm.2015.2190

Gemfibrozil attenuates the inflammatory response and protects rats from abdominal sepsis

Authors:
- Carlos R. Cámara‑Lemarroy
- Francisco J. Guzman‑De La Garza
- Paula Cordero‑Perez
- Juan M. Ibarra‑Hernandez
- Linda E. Muñoz‑Espinosa
- Nancy E. Fernandez‑Garza
View Affiliations

Affiliations: Department of Internal Medicine, University Hospital 'José Eleuterio González', Autonomous University of Nuevo León, Monterrey, Nuevo León 64460, Mexico, Department of Physiology, School of Medicine, Autonomous University of Nuevo León, Monterrey, Nuevo León 64460, Mexico, Liver Unit, Department of Internal Medicine, University Hospital 'José Eleuterio González', Autonomous University of Nuevo León, Monterrey, Nuevo León 64460, Mexico
Published online on: January 19, 2015 https://doi.org/10.3892/etm.2015.2190
Pages: 1018-1022

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sepsis is a serious condition characterized by an infectious process that induces a severe systemic inflammatory response. In this study, the effects of gemfibrozil (GFZ) on the inflammatory response associated with abdominal sepsis were investigated using a rat model of cecal‑ligation and puncture (CLP). Male Wistar rats were randomly divided into three groups: Sham‑operated group (sham), where laparotomy was performed, the intestines were manipulated, and the cecum was ligated but not punctured; control group, subjected to CLP; and GFZ group, which received GFZ prior to undergoing CLP. The groups were then subdivided into three different time‑points: 2, 4 and 24 h, indicating the time at which blood samples were obtained for analysis. Serum concentrations of tumor necrosis factor‑α (TNF‑α), interleukin‑1 (IL‑1), malondialdehyde (MDA), aspartate aminotransferase (AST), alanine aminotransferase (ALT) and lactate dehydrogenase (LDH) were determined. The LDH, AST and ALT values were significantly elevated following CLP compared with those in the sham group, and GFZ treatment was able to reduce these elevations. GFZ also reduced the sepsis‑induced elevations of TNF‑α and IL‑1. In conclusion, GFZ treatment was able to attenuate the inflammatory response associated with CLP‑induced sepsis, by diminishing the release of inflammatory cytokines, thereby reducing tissue injury and oxidative stress.

View Figures

View References

1	Nduka OO and Parrillo JE: The pathophysiology of septic shock. Crit Care Clin. 25:677–702. 2009. View Article : Google Scholar : PubMed/NCBI
2	Cinel I and Opal SM: Molecular biology of inflammation and sepsis: a primer. Crit Care Med. 37:291–304. 2009. View Article : Google Scholar
3	Dellinger RP, Levy MM, Carlet JM, et al: Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med. 34:17–60. 2008. View Article : Google Scholar :
4	Neyrinck AP, Liu KD, Howard JP and Matthay MA: Protective mechanisms of activated protein C in severe inflammatory disorders. Br J Pharmacol. 158:1034–1047. 2009. View Article : Google Scholar : PubMed/NCBI
5	Ranieri VM, Thompson BT, Barie PS, et al: PROWESS-SHOCK Study Group: Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 366:2055–2064. 2012. View Article : Google Scholar : PubMed/NCBI
6	Parrish WR, Gallowitsch-Puerta M, Czura CJ and Tracey KJ: Experimental therapeutic strategies for severe sepsis: mediators and mechanisms. Ann NY Acad Sci. 1144:210–236. 2008. View Article : Google Scholar : PubMed/NCBI
7	Michalik L and Wahli W: Involvement of PPAR nuclear receptors in tissue injury and wound repair. J Clin Invest. 116:598–606. 2006. View Article : Google Scholar : PubMed/NCBI
8	Delayre-Orthez C, Becker J, Guenon I, Lagente V, Auwerx J, Frossard N and Pons F: PPARalpha downregulates airway inflammation induced by lipopolysaccharide in the mouse. Respir Res. 6:912005. View Article : Google Scholar : PubMed/NCBI
9	Yang TL, Chen MF, Luo BL, Xie QY, Jiang JL and Li YJ: Fenofibrate decreases asymmetric dimethylarginine level in cultured endothelial cells by inhibiting NF-kappaB activity. Naunyn Schmiedebergs Arch Pharmacol. 371:401–407. 2005. View Article : Google Scholar : PubMed/NCBI
10	Zambon A, Gervois P, Pauletto P, Fruchart JC and Staels B: Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidence. Arterioscler Thromb Vasc Biol. 26:977–986. 2006. View Article : Google Scholar : PubMed/NCBI
11	Ozansoy G, Akin B, Aktan F and Karasu C: Short-term gemfibrozil treatment reverses lipid profile and peroxidation but does not alter blood glucose and tissue antioxidant enzymes in chronically diabetic rats. Mol Cell Biochem. 216:59–63. 2001. View Article : Google Scholar : PubMed/NCBI
12	Roy A and Pahan K: Gemfibrozil, stretching arms beyond lipid lowering. Immunopharmacol Immunotoxicol. 31:339–351. 2009. View Article : Google Scholar : PubMed/NCBI
13	Dasgupta S, Roy A, Jana M, Hartley DM and Pahan K: Gemfibrozil ameliorates relapsing-remitting experimental autoimmune encephalomyelitis independent of peroxisome proliferator-activated receptor-alpha. Mol Pharmacol. 72:934–946. 2007. View Article : Google Scholar : PubMed/NCBI
14	Sivarajah A, Chatterjee PK, Hattori Y, et al: Agonists of peroxisome-proliferator activated receptor-alpha (clofibrate and WY14643) reduce renal ischemia/reperfusion injury in the rat. Med Sci Monit. 8:BR532–BR539. 2002.PubMed/NCBI
15	Nanji AA, Dannenberg AJ, Jokelainen K and Bass NM: Alcoholic liver injury in the rat is associated with reduced expression of peroxisome proliferator-alpha (PPARalpha)-regulated genes and is ameliorated by PPARalpha activation. J Pharmacol Exp Ther. 310:417–424. 2004. View Article : Google Scholar : PubMed/NCBI
16	Hubbard WJ, Choudhry M, Schwacha MG, Kerby JD, Rue LW III, Bland KI and Chaudry IH: Cecal ligation and puncture. Shock. 24(Suppl 1): 52–57. 2005. View Article : Google Scholar : PubMed/NCBI
17	Wu WT, Lee CC, Lee CJ, Subeq YM, Lee RP and Hsu BG: Rosiglitazone ameliorates endotoxin-induced organ damage in conscious rats. Biol Res Nurs. 13:38–43. 2011. View Article : Google Scholar
18	Standage SW, Caldwell CC, Zingarelli B and Wong HR: Reduced peroxisome proliferator-activated receptor α expression is associated with decreased survival and increased tissue bacterial load in sepsis. Shock. 37:164–169. 2012. View Article : Google Scholar :
19	Wiel E, Lebuffe G, Robin E, et al: Pretreatment with peroxysome proliferator-activated receptor alpha agonist fenofibrate protects endothelium in rabbit Escherichia coli endotoxin-induced shock. Intensive Care Med. 31:1269–1279. 2005. View Article : Google Scholar : PubMed/NCBI
20	Jozefowicz E, Brisson H, Rozenberg S, et al: Activation of peroxisome proliferator-activated receptor-alpha by fenofibrate prevents myocardial dysfunction during endotoxemia in rats. Crit Care Med. 35:856–863. 2007. View Article : Google Scholar : PubMed/NCBI
21	Hill MR, Clarke S, Rodgers K, Thornhill B, Peters JM, Gonzalez FJ and Gimble JM: Effect of peroxisome proliferator-activated receptor alpha activators on tumor necrosis factor expression in mice during endotoxemia. Infect Immun. 67:3488–3493. 1999.PubMed/NCBI
22	van der Poll T and van Deventer SJ: Cytokines and anticytokines in the pathogenesis of sepsis. Infect Dis Clin North Am. 13:413–426. 1999. View Article : Google Scholar : PubMed/NCBI
23	Xu J, Chavis JA, Racke MK and Drew PD: Peroxisome proliferator-activated receptor-alpha and retinoid X receptor agonists inhibit inflammatory responses of astrocytes. J Neuroimmunol. 176:95–105. 2006. View Article : Google Scholar : PubMed/NCBI
24	Takano H, Nagai T, Asakawa M, et al: Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes. Circ Res. 87:596–602. 2000. View Article : Google Scholar : PubMed/NCBI
25	Rosenson RS: Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients. Obesity (Silver Spring). 17:504–509. 2009. View Article : Google Scholar
26	Zhao SP, Ye HJ, Zhou HN, Nie S and Li QZ: Gemfibrozil reduces release of tumor necrosis factor-alpha in peripheral blood mononuclear cells from healthy subjects and patients with coronary heart disease. Clin Chim Acta. 332:61–67. 2003. View Article : Google Scholar : PubMed/NCBI
27	Cheng SM, Chu KM and Lai JH: The modulatory mechanisms of fenofibrate on human primary T cells. Eur J Pharm Sci. 40:316–324. 2010. View Article : Google Scholar : PubMed/NCBI
28	Stienstra R, Mandard S, Tan NS, et al: The interleukin-1 receptor antagonist is a direct target gene of PPARalpha in liver. J Hepatol. 46:869–877. 2007. View Article : Google Scholar : PubMed/NCBI
29	Liu SF and Malik AB: NF-kappaB activation as a pathological mechanism of septic shock and inflammation. Am J Physiol Lung Cell Mol Physiol. 290:L622–L645. 2006. View Article : Google Scholar
30	Delerive P, Gervois P, Fruchart JC and Staels B: Induction of IkappaB alpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J Biol Chem. 275:36703–36707. 2000. View Article : Google Scholar : PubMed/NCBI
31	Ji Y, Wang Z, Li Z and Liu J: Modulation of LPS-mediated inflammation by fenofibrate via the TRIF-dependent TLR4 signaling pathway in vascular smooth muscle cells. Cell Physiol Biochem. 25:631–640. 2010. View Article : Google Scholar : PubMed/NCBI
32	Galley HF: Oxidative stress and mitochondrial dysfunction in sepsis. Br J Anaesth. 107:57–64. 2011. View Article : Google Scholar : PubMed/NCBI
33	Maitra U, Chang S, Singh N and Li L: Molecular mechanism underlying the suppression of lipid oxidation during endotoxemia. Mol Immunol. 47:420–425. 2009. View Article : Google Scholar : PubMed/NCBI
34	Victor VM and De la Fuente M: Immune cells redox state from mice with endotoxin-induced oxidative stress. Involvement of NF-kappaB. Free Radic Res. 37:19–27. 2003. View Article : Google Scholar : PubMed/NCBI
35	Koksal GM, Sayilgan C, Aydin S, Oz H and Uzun H: Correlation of plasma and tissue oxidative stresses in intra-abdominal sepsis. J Surg Res. 122:180–183. 2004. View Article : Google Scholar : PubMed/NCBI
36	Olukman M, Sezer ED, Ulker S, Sözmen EY and Cınar GM: Fenofibrate treatment enhances antioxidant status and attenuates endothelial dysfunction in streptozotocin-induced diabetic rats. Exp Diabetes Res. 2010:8285312010. View Article : Google Scholar
37	Boshra V and Moustafa AM: Effect of preischemic treatment with fenofibrate, a peroxisome proliferator-activated receptor-α ligand, on hepatic ischemia-reperfusion injury in rats. J Mol Histol. 42:113–122. 2011. View Article : Google Scholar : PubMed/NCBI
38	Lorente JA and Marshall JC: Neutralization of tumor necrosis factor in preclinical models of sepsis. Shock. 24(Suppl 1): 107–119. 2005. View Article : Google Scholar : PubMed/NCBI
39	Szakmany T, Hauser B and Radermacher P: N-acetylcysteine for sepsis and systemic inflammatory response in adults. Cochrane Database Syst Rev. 9:CD0066162012.PubMed/NCBI
40	Mermis JD and Simpson SQ: HMG-CoA reductase inhibitors for prevention and treatment of severe sepsis. Curr Infect Dis Rep. 14:484–492. 2012. View Article : Google Scholar : PubMed/NCBI